Takeda looks to build vaccines business

Share this article:
Takeda is getting into vaccines with the launch of a dedicated global division that will make use of Nycomed A/S's business infrastructure in Europe and emerging markets.

The initial focus of the Tokyo-based business will be on Asian markets where Takeda has local sales subsidiaries, including China and India, and it will make use of the company's R&D operations in Osaka and Hikari, but “all other operations will be established in Chicago, in anticipation of global development of the vaccine business,” said Takeda spokesman Hisashi Tokinoya. That includes planning and coordination, responsible for mapping mid- and long-term strategy for the unit, and business development, charged with plotting opportunities for global expansion and alliances. The unit will launch with 70 employees, mostly Japan-based vaccine specialists working on R&D.

The new division will be headed by Dr. Rajeev Venkayya, who joins the firm from the Bill & Melinda Gates Foundation, where he was director of vaccine delivery in the Global Health Program, overseeing the foundation's polio eradication efforts and investment in the Global Alliance for Vaccines and Immunization. He was previously special assistant to the president for biodefense at the White House, in which capacity he headed development and implementation of the National Strategy for Pandemic Influenza.

The company has manufactured pediatric vaccines for six decades and is currently working on vaccines for HPV, Haemophilius Influenzae type b (Hib) and polio. Takeda is also “expediting preparations for production and supply” of pandemic flu vaccines.
Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...